ImmuCell Corporation ICCC
9.93
(0.04)
(0.40%)
as of 25 Sep
- Market cap
- $90.6M
- P/E
- 117×
Follow ICCC
Insider Buys
alert about insiders buying in the last 12 month
| Jun '26 | Mar '26 | Dec '25 | Sep '25 | Older periods | |
|---|---|---|---|---|---|
| 2.57% | (1.88%) | (3.81%) | 8.27% |
+8 more TTM periods Free account |
|
| 1.69% | (1.22%) | (2.37%) | 5.15% | ||
ROIC |
7.84% | 5.04% | 3.19% | 4.11% | |
Return on Tangible Assets |
2.09% | (1.53%) | (3.05%) | 6.25% | |
Average Days of Receivables |
34.47 | 32.85 | 45.14 | 33.58 | |
Free Cash Flow per Share |
0.47 | 0.38 | 0.14 | 0.08 | |
Free Cash Flow |
4.23 | 3.42 | 1.26 | 0.75 | |
Capital Expenditures |
(1.66) | (1.05) | (1.21) | (1.24) | |
Piotroski F-Score |
7.00 | 6.00 | 7.00 | 7.00 | |
| Other line items | |||||
Cash ROIC |
12.14% | 10.02% | 6.19% | 4.61% | |
Accounts Receivable Turnover |
11.63 | 9.91 | 7.69 | 11.42 | |
Accounts Payable Turnover |
6.79 | 8.25 | 6.80 | 6.79 | |
Inventory Turnover |
2.11 | 2.14 | 1.98 | 1.90 | |
Average Days of Payables |
55.98 | 46.64 | 51.43 | 51.71 | |
Days of Inventory on Hand |
181.00 | 184.22 | 208.82 | 218.12 | |
Tax Rate |
(0.08) | 0.04 | 0.01 | (0.01) | |
Research and Development Expense of Revenue |
6.16% | 8.70% | 11.00% | 11.17% | |
Selling, General and Administrative Expense of Revenue |
28.07% | 25.54% | 24.43% | 21.37% | |
Share Based Compensation of Revenue |
1.81% | 1.27% | 1.07% | 0.94% | |
Interest Coverage |
0.00 | 0.00 | 0.00 | 0.00 | |
Operating CF/Net income |
7.48 | (8.21) | (2.38) | 0.86 | |
Depreciation/Fixed assets |
0.12 | 0.13 | 0.13 | 0.11 | |
Capex/Depreciation |
(0.69) | (0.40) | (0.44) | (0.45) | |
Revenue per Share |
3.38 | 3.31 | 3.06 | 3.07 | |
Operating CF per Share |
0.65 | 0.49 | 0.27 | 0.22 | |
Capex per Share |
(0.18) | (0.12) | (0.13) | (0.14) | |
Capex to Sales |
0.05 | 0.04 | 0.04 | 0.04 | |
Net Profit Margin |
2.57% | (1.82%) | (3.76%) | 8.37% |
Columns are period end dates